Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives. Clin Mol Hepatol. 2023;29:320–331

Article  PubMed  PubMed Central  Google Scholar 

Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, et al. Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection. Clin Gastroenterol Hepatol. 2019;17(1348–1355): e1342

Google Scholar 

Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211:374–382

Article  CAS  PubMed  Google Scholar 

Lin HY, Tseng TC. Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: facts and puzzles. Clin Mol Hepatol. 2022;28:181–182

Article  PubMed  PubMed Central  Google Scholar 

Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–195

Article  PubMed  Google Scholar 

Hwang EG, Jung EA, Yoo JJ, Kim SG, Kim YS. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int. 2023;17:860–869

Article  PubMed  Google Scholar 

Park JW, Yoo JJ, Kim SG, Kim YS. Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. Hepatol Int. 2024. https://doi.org/10.1007/s12072-024-10664-8

Article  PubMed  Google Scholar 

Daher D, Dahan KSE, Singal AG. Non-alcoholic fatty liver disease-related hepatocellular carcinoma. J Liver Cancer. 2023;23:127–142

Article  PubMed  PubMed Central  Google Scholar 

Jang W, Lee HW, Lee JS, Kim BK, Kim SU, Park JY, et al. Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology. J Liver Cancer. 2022;22:158–166

Article  PubMed  PubMed Central  Google Scholar 

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–681

Article  CAS  PubMed  Google Scholar 

Byun KS, Choi J, Kim JH, Lee YS, Lee HC, Kim YJ, et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20(427–437): e425

Google Scholar 

Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE. 2022;17: e0261760

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: a prospective real-world clinical study. Antivir Ther. 2022;27:13596535221082400

Article  CAS  Google Scholar 

Gazzola L, Tagliaferri G, De Bona A, Mondatore D, Borsino C, Bini T, et al. Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance? HIV Med. 2021;22:140–145

Article  CAS  PubMed  Google Scholar 

Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL cholesterol and triglycerides. Open Forum Infect Dis. 2022;9:621

Article  Google Scholar 

Jeong J, Shin JW, Jung SW, Park EJ, Park NH. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin Mol Hepatol. 2022;28:254–264

Article  PubMed  Google Scholar 

Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46:599–604

Article  CAS  PubMed  Google Scholar 

Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441–453

Article  PubMed  Google Scholar 

Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52

Article  CAS  PubMed  Google Scholar 

Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168–180

Article  CAS  PubMed  Google Scholar 

Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:3

Article  Google Scholar 

Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;56:2863–2871

Article  CAS  PubMed  Google Scholar 

Luangrath V, Brodeur MR, Rhainds D, Brissette L. Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism in vivo. Arterioscler Thromb Vasc Biol. 2008;28:1290–1295

Article  CAS  PubMed  Google Scholar 

Brundert M, Heeren J, Merkel M, Carambia A, Herkel J, Groitl P, et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res. 2011;52:745–758

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim LY, Kim JY, Yoo JJ, Kim SG, Kim YS. Tenofovir disoproxil fumarate versus entecavir: effects on lipid profiles and cardiovascular outcomes in people living with chronic hepatitis B. J Med Virol. 2025;97: e70187

Article  PubMed  Google Scholar 

Fung SK, Pan CQ, Wong GL, Seto WK, Ahn SH, Chen CY, et al. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Aliment Pharmacol Ther. 2024;59:217–229

Article  CAS  PubMed  Google Scholar 

Hong H, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, et al. Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide. Clin Mol Hepatol. 2024;30:49–63

Article  PubMed  Google Scholar